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Implantable drug delivery systems have attracted a great deal of attention in recent 
years. In these applications, usually active agents (e.g., drugs, growth hormones, etc.), 
which are released in their environment, are loaded into a host hydrogel or polymeric 
fibre and thus may provide a healthy environment and enhance regeneration of the 
surrounding tissue. Although hydrogel structures have shown good efficiency in 
releasing the different types of drugs, it is worth mentioning that due to their burst 
release kinetics, they usually cannot be applied in controlled drug release systems. 
Therefore, there are many attempts to develop new structures to overcome this 
problem.  
In this work, we introduce a coaxial wet-spinning method to develop novel 
polycaprolactone (PCL)/alginate and PCL/chitosan coaxial fibres for future 
application for controlled drug delivery. A coaxial wet-spinning assembly strategy is 
proposed to readily prepare core-sheath fibrous structures. Fine and continuous coaxial 
fibres with the sheath of polycaprolactone and core of alginate or chitosan were 
prepared by necessary wet spinning conditions. By applying this procedure, coaxial 
fibres with a broad compositional range and controllable diameters were fabricated. 
The morphological and mechanical properties of these fibres were studied, with release 
profiles from the coaxial fibers determined using a model component. Our results 
suggest that unlimited length of designed coaxial PCL/alginate and PCL/chitosan 
fibres can be produced giving potential to create 3D textile structures. Moreover, these 
designed coaxial fibres could be potential candidates for tissue engineering with the 
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1 INTRODUCTION AND LITERATURE REVIEW 
1.1 Drug Delivery Systems 
Drug delivery systems (DDS) describe a formulation or device that allows the 
introduction of a therapeutic material into the body and advances its efficacy and safety 
by regulating the amount, period, and location of drug release in the body. This 
procedure comprises the administration of the therapeutic product, the release of the 
active components by the product, and the later transport of the active components 
through the biological membranes to the site of action. The method by which a drug is 
delivered can have a significant effect on its efficacy. Conventional drug delivery 
systems comprise injections, oral formulations (solutions, suspensions, tablets and 
capsules), topical creams and ointments which are commonly used in practice. Among 
those, oral administration is the most preferable route of administration, being 
convenient, controlled by the patient and requiring no skilled medical intervention. 
Such a simple route of delivery possesses many disadvantages. For example, many 
drugs cannot be given by this route due to poor absorption characteristics with the 
tendency to degrade in the gastrointestinal tract. A potential alternative way of 
administering drugs via routes such as oral trans-mucosal, transdermal, nasal, 
pulmonary, vaginal, ophthalmic, and central nervous system[1] have been developed to 
overcome the limitation of oral drug delivery system.  Improving the safety efficacy 
ratio of conventional drug delivery has been attempted using different methods such 
as individualizing drug therapy, dose titration, and therapeutic drug monitoring. 
Delivering the drug at a controlled rate, slow delivery, and targeted delivery are other 
very attractive methods which have been pursued vigorously. 
Controlled release drug delivery systems represent one of the very important areas of 
health care[3]. Different types of carrier base drug delivery systems have been designed 
for this purpose such as liposomes, proliposomes, microspheres, gels, prodrugs, and 
cyclodextrins. Liposomal drug delivery systems provide good control over infectious 
diseases, cancer, lung-specific disease, brain tumours[4]. Compared to systemic 
therapy, these delivery systems have several advantages, such as reduced toxicity, 
better efficacy, and improved patient compliance. For example, systemic 




therapeutic effect due to the substantial loss of these drugs before they reach their 
target cancer cells. Substantial loss of the administered drug can be due to partial 
degradation and immediate drug excretion by body organs[2].  
These high doses typically give rise to whole body toxicity as a result of the drug 
absorption by other tissues and organs that entails devastating side effects. However, 
limitations such as lower drug bioavailability and higher drug degradation and loss 
have prompted the development of novel tools to enhance drug delivery, whereby the 
specific targeting of cancer cells, through local drug delivery, would reduce systemic 
related toxicities. 
Many different drug delivery carriers have been investigated over the past three 
decades which can be either injected or implanted in the body[5] such as natural 
polymers[6,7], synthetic polymers[8], nanoparticles[9–12], microcapsules[13–15], and 
polymeric implants[16,17]. Implanting medical devices through surgical procedure 
improves millions of patients’ quality of life every year[18]. Development in DDS in 
recent years has promoted the need for biomaterials with degradable properties. 
Recently, synthetic and natural biodegradable polymers have attracted the attention of 
researchers for the use as carriers for drug delivery[19,20] and medical devices. Table 





















absorbable sutures, implantable contact 
lenses, sponge wound dressing, drug 
delivery system 
Albumin cell and drug microencapsulation, albumin-
binding surfaces[22] for implantable devices 
Poly (amino acids) oligomeric drug carrier 
Carboxymethyl cellulose cell immobilization via a combination of 
ionotropic gelation and polyelectrolyte 
complex formation (e.g. with chitosan), in 
drug-delivery systems and dialysis 
membranes. 
Alginate (marine sources, 
algae) 
controlled release of bioactive substances, 
injectable microcapsules for treating 




























Poly(lactic acid) sutures, drug delivery systems, tissue 
engineering, and implantable devices 
poly(glycolic acid) sutures, drug delivery systems, tissue 
engineering, and implantable devices 
poly(-caprolactone)  drug-eluting stents, sutures, and implantable 
devices 




oxygenator membrane, vascular graft, 
catheter coating, soft tissue augmentation, 
vascular prostheses 
Polymethylmethacrylate dental restorations, intraocular lenses, joint 
replacement, e.g. bone cements 
Poly(dioxanone) orthopaedics, plastic surgery, cardiovascular 






The spinning process enables fibre extrusion at room temperature with drugs and 
therapeutic agents which can be incorporated in implant devices. For drug delivery, 
fibres have additional advantages such as strong mechanical properties, positional 
stability, uniform diameter, uniform drug concentration, and controlled release due to 
the porosity of the fibrous structure. Furthermore, the devices can be readily mass 
produced. Among the fibre manufacturing methods; melt spinning, electrospinning 
and wet spinning, the latter offers the strongest fibres and the widest range of drugs 
that can be incorporated into such a structure. However, this method uses organic 
solvents which must be removed from the fibre. This can be done by the use of 
different solvent baths. These manufacturing processes allow for tunable controlled 
drug delivery[23]. A biodegradable drug-loaded fibre trademarked ELUTE® is 
commercially available for pharmaceuticals (now TissueGen Company). 
1.2 Fibre Spinning Technologies 
The process of forming fibres from polymers (melt or gel) is referred to as “fibre 
spinning”. Depending on the properties of the polymer (physical and chemical), there 
are two general methods for fibre spinning; melt spinning and gel spinning.  Gel 
spinning itself can be divided into; dry spinning or wet spinning, based on the fibre 
solidification process[24,25]. 
1.2.1 Wet-spinning 
Wet spinning is a non-solvent-induced phase inversion technique where polymeric 
fibres are produced through an immersion-precipitation process. This is the oldest 
spinning method which was initially used for the spinning of rayon fibres[25]. In wet 
spinning, the polymer solution is prepared in a suitable solvent, then extruded at a 
controlled flow rate into a coagulation bath containing a non-solvent. Inward mass 
transfer of the non-solvent and outward mass transfer of solvent in the filament inside 
the coagulation bath results in the process of solidification. The coagulation rate 
(influenced by the mass transfer rate between solvent and non-solvent) affects 
morphology (i.e. cross-section) of the final fibre. 
Figure 1-1 shows the schematic images of lab scale wet-spinning setup and rotary 
coagulation bath. Aramid, acrylic, modified acrylic, polyaniline, and spandex can be 




fibres made of natural polymers such as chitosan[27], and regenerated silk fibron[28–30] 
have been reported.  
Wet-spun chitosan[31] and poly (L-lactic acid) (PLLA)[32] fibres have been used as drug 
carrier/releasing devices. Chitosan fibres as well as PCL[33] and braided PLLA 
fibres[34] have also been used in tissue engineering applications. 
Biodegradable fibres for the controlled delivery of dexamethasone or levofloxacin 
were studied by Mack et al.[35]. In their study, poly (lactide-co-glycolide) (PLGA) 
fibres were prepared by wet-spinning solutions while the drug was dissolved in 
dimethyl sulfoxide (DMSO) in a coagulation bath of water. Fibres loaded with 
levofloxacin were implanted in the eyes of the New Zealand white rabbit, showing 
effective levels of levofloxacin in the tears for 6 days[35].  
PCL fibres with a hollow structure have the potential for many applications due to 
their high porosity. Coaxial PCL/PEO hollow microfibres have been fabricated by 
Rubert et.al[36]; in their study, Dexamethasone was encapsulated in highly porous 
micro-fibres to regulate chronic inflammations[36]. Moreover, PCL hollow micro-
fibres have previously been produced by phase separation methods using different 
coagulation baths for vascular tissue engineering applications. These fibres are 






Figure 1-1 Illustration of lab scale wet-spinning apparatus a) long bath coagulation 
line and b) rotary coagulation bath. 
 
1.2.2 Coaxial wet-spinning 
Unlike the coaxial electrospinning technology that has been utilised to spin core-sheath 
nanofibres, the coaxial wet-spinning approach is not a well-established method for the 
preparation of coaxial microfibers. This is due to the extreme difficulty of selecting 




Using the coaxial system to obtain multi-layered fibres is quite a novel method in the 
wet-spinning process. 
Coaxial wet-spinning of alginate hollow fibres was reported by Hu et al[38]. In their 
study, hollow and solid hydrogel fibres with different diameters were spun by a triple-
orifice spinneret. 
Another approach to create coaxial fibres has been described by Ucar et al[39]. They 
produced a chitosan fibre core coated with alginate as a sheath. Gentamicin (a model 
antibiotic) was incorporated into the scaffold and its release kinetics measured. These 
scaffolds are potentially useful for tissue engineering with the feature of controlled 
delivery of the bioactive agent[39].  
Bio-polymeric core-sheath fibres incorporating an inner core of chitosan and alginate 
as the sheath, were fabricated by Mirabedini et al.[40] to utilise as 3D tissue scaffolds 
capable of drug delivery[40].One of the advantages of this coaxial method is the 
utilisation of properties of both materials in the fibre, allowing it to be used in different 
applications. For instance, materials with different hydrophilicity can be utilised to 
overcome the solubility limitation of drugs[41].Another advantage is that burst release 
kinetics of an encapsulated drug may be decreased, providing a longer, more sustained 
release profile. For example, encapsulating the drug in a hydrogel based material and 
thus protecting the structure by a hydrophobic surface can enhance the release profile 





1.3 Synthetic Biodegradable Polymers 
“Biomaterial” refers to classes of materials which interact with biological systems. 
Polymers are a subset of biomaterials that can play a major role in human health system 
due to their biocompatibility and biodegradability. The complexity and diversity of the 
in vivo environment limits the types of materials that can be used in biomedical 
applications, therefore, polymers with a diverse range of properties are needed. 
Biodegradable polymers have been widely utilised and greatly facilitated the 
development of biomedical applications in the past two decades due to their 
biocompatibility and biodegradability[42]. There are a wide range of materials used in 
biomedical applications including organic and inorganic chemicals and metal alloys. 
Depending on the application, specific properties of biomaterials are required, for 
example; cell adhesion and biocompatibility are required in tissue engineering. 
According to their specific properties, polymers can be categorized into; polymers with 
responsive activities and polymers with reactive groups. In particular, polymeric 
biomaterials incorporating various functional groups, such as carboxyl, hydroxyl, 
amino, ketal, bromo, chloro, carbon–carbon double bonds or triple bonds, etc., are 
highly sought after. 
Other polymers may be responsive to temperature, pH, or redox conditions. A number 
of polypeptides bearing pendant ionizable groups such as poly(glutamic acid), 
poly(aspartic acid), poly(histidine), poly(lysine) and poly(arginine) exhibit pH-
responsive properties. 
Poly (lactic acid) (PLA), poly (glycolic acid), poly (-caprolactone) (PCL) and their 
copolymers are aliphatic polyesters and have been widely investigated for biomedical 
applications due to their biodegradability, bioresorbability, and biocompatibility[19,42]. 
Poly--caprolactone (PCL), known for its excellent biostability and processability was 
selected for investigation as part of this thesis and findings reported herein. 
1.3.1 Polycaprolactone (PCL) 
PCL is a linear aliphatic polyester and one of the earliest polymers synthesized by the 
Carothers group in the early 1930s[43]. PCL can be produced by two methods; 
condensation of 6-hydroxycaproic (6-hydroxyhexanioc) acid and ring opening 
polymerization (ROP) of -caprolactone. The preferred method is ROP as it yields a 




four main mechanisms of ROP based on catalyst; anionic, cationic, monomer-
activated, and coordination-insertion ROP. Anionic ROP results in formation of an 
anionic species which then attacks the carbonyl carbon of the monomer. The carbonyl 
oxygen of the monomer attacks the cationic species which is formed by cationic ROP. 
In monomer–activated ROP the activated monomer attacks the polymer chain end. The 
most common method of ROP involves coordination of the monomeric species to the 
catalyst and insertion of the monomer into the metal-oxygen bond of the catalyst[44]. 
The average molecular weight of polycaprolactone varies from 3 to 80 kDa which can 
be graded by molecular weight and changed, depending on sources and preparation 
methods[45]. PCL is a semi-crystalline polymer with glass transition temperature (Tg) 
of -60 ◦C and melting point range between 59 and 64 ◦C, dictated by the crystalline 







Figure 1-2 Mechanism of the initiation step for a) anionic[47], b) cationic[47,48], c) 
monomer-activated[49,50], and d) coordination-insertion ring opening 
polymerization[47,48] (ROP) of ε-caprolactone to form polycaprolactone. 
PCL is soluble in chloroform, dichloromethane (DCM), carbon tetrachloride, benzene, 
toluene, cyclohexanone and 2-nitropropane at room temperature. However, higher 
temperatures are needed for PCL to dissolve in 2-butanone, acetone, ethyl acetate, 
dimethylformamide (DMF) and acetonitrile. PCL is insoluble in petroleum ether, 
diethyl ether, and alcohols[51]. Due to its slow degradation, FDA approval, nontoxic 
properties, ability to encapsulate many diverse drugs, and excellent tensile properties, 
PCL has been investigated for use as a long term drug delivery device[19]. 
PCL can be applied to drug delivery as a microsphere or nanosphere[52]. Human basic 
fibroblast growth factor (bFGF) loaded PCL-PEG-PCL nanoparticles have been 
studied by Gou. M et al. [53] Such nanoparticles may have potential as anti-tumor 
vaccines. Encapsulation efficacy of this nanoparticle has been reported as 61% which, 




total bFGF release[53]. It can be also used as a membrane with incorporation of other 
material as controlled release devices for bioactive molecules and extended-residence 
support for cell growth. Other researchers showed that owing to its capability to deliver 
bioactive molecules such as growth factors and hormones, PCL is able to deliver anti-
cancer drugs for cancer treatment[54,55]. 
DOX-loaded (poly[ethylene glycol]--polycaprolactone) di-block copolymer (MP) 
gel exhibited remarkable in vitro anti-proliferative activities against B16F10 cancer 
cells. In vivo experiments employing B16F10 cancer cell xenograft-bearing mice 
showed that a single intra-tumoral injection of DOX-loaded MP gel inhibited the 
growth of tumours as effectively as repeated injections of free DOX, and more 
effectively than a single dose of free DOX (Figure 1-3)[54]. This study was also 
successful in reducing the DOX level in other organs consequently lower side-effects 
were observed in comparison with free DOX injection. 
PCL can also be utilised in medical devices as sutures[56,57], wound dressings[58], 
contraceptive devices[59], fixation devices[60], and dentistry[61]. For example, the long-
term contraceptive device Capronors® has been developed for the zero order release 
of levonorgestrel and is composed of PCL[62]. PCL is also applied in tissue 
engineering[63,33] and textile fabrication for tissue engineering of the aortic valve[64]. 
However, for tissue engineering purposes, PCL has some disadvantages such as a low 
rate of degradation[43]. Nevertheless, the ability of PCL to be blended with other 
polymers could potentially overcome this disadvantage. For example, biocompatible 
and biodegradable PCL-sebacic acid (PCL-SA) blend was developed to increase the 






Figure 1-3 Inhibitory effects of saline, Doxorubicin-loaded (poly[ethylene glycol]--
polycaprolactone) di-block copolymer MP, repeated injections of free DOX (0.4 mg) 
and a single injection of DOX (0.4 mg)-loaded MP gel. The image of excised tumor 
masses at the time of sacrifice after 1, 15, and 20 days post treatment from B16F10 
cancer cells xenograft-bearing mice[54]. 
1.4 Hydrogels 
Hydrogels are characterised as being three dimensional polymer networks containing 
crosslinked (chemical or physical) hydrophilic polymer chains. Hydrogels readily 
swell in aqueous solutions due to their hydrophilicity, however they do not dissolve 
due to their cross-linked nature[66,67]. Hydrogen bonding, hydrophobic interactions and 
crystalline formation are examples of physical crosslinks. The degree of chemical 
cross-linking, which creates a covalently cross-linked network,[68] significantly effects 
the physical and mechanical properties of hydrogels [68].  
Most hydrogels will respond to some physiological stimuli present in the body such as 
temperature[69,70], pH[71], and certain substances[72]. The hydrogels respond by 
changing form, mostly reflected as a change in volume, due to a change in their water 
content. Hydrogels have been of interest for use in biological applications due to their 
capability of mimicking the appearance and properties of many soft, natural tissues[73]. 
Moreover, their properties such as flexibility, swelling, diffusion, and also their 
mechanical and physical behaviour make them appealing as potential implantable drug 




and chemical properties such as permeability, biodegradability, and surface 
functionality need to be fine-tuned. Some models have been previously advanced to 
predict the release of an active agent from a hydrogel device over a period of time. 
These models included diffusion-controlled, swelling-controlled, and chemically-
controlled hydrogels[76]. 
Depending on their properties, hydrogels may exhibit different chemical and physical 
interactions with drugs, giving rise to varying drug release mechanisms. Figure 1-4 
outlines various controlled release mechanisms from hydrogels. Chitosan and alginate 
were two selected hydrogels for study as part of this thesis due to their well know 







Figure 1-4 Schematic illustration of various drug release mechanisms from 
hydrogels[73]. a) Dissolved drug in polymer diffused out of hydrogel due to mass 
transfer. Dissolution rate is commonly controlled by diffusion, b) release based on 
polymer surface erosion and diffusion of drug into media, c) hydrogel containing drug 
encapsulated in a secondary controlled release device such as liposomes, 
nanoparticles, and micelles, d) swelling of hydrogel due to the ability of high water 






1.4.1 Chitosan  
Chitosan is the deacetylated or partially deacetylated form of the natural polymer chitin 
in the presence of alkaline substances. Chitin is sourced from the exoskeleton of 
insects, crustaceans and fungi. It is a linear polysaccharide, composed of glucosamine 
and N-acetyl glucosamine units linked by β (1–4) glycosidic bonds [77] (Figure 1-5). 
 
 
Figure 1-5  Chemical structure of chitosan[78]. 
The structure of chitosan varies depending on the proportion of N-acetyl-D-
glucosamine and D-glucosamine residues, with the content of glucosamine referred to 
as “the degree of deacetylation (DD)”; directly effecting the chemical and biological 
properties of the polymer as well as its molecular weight. Generally, when the DD of 
chitin is higher than 50% it becomes soluble in an aqueous acidic medium (below pH 
6.0). This is due to the protonation of amine groups which have a pKa value of 6.3 
forming a water-soluble, cationic, polyelectrolyte chitosan. The presence of amino 
groups indicate that pH substantially alters the charged state and therefore the 
properties of chitosan[79] (Figure 1-6). The DD impacts on the biodegradability of this 
polymer, for example, a DD above 69% decreases in vivo degradation of the 
polymer[80,81]. Chitosan has unique and attractive properties  for potential use in drug 
delivery systems, such as low cost, availability (deacetylated from chitin, the second 
most abundant natural polymer), biocompatibility, and biodegradability,[82] with its 
degradation products being non-toxic, non-immunogenic and non-carcinogenic[83]. 
In-vitro degradation of chitosan occurs through the action of enzymes such as 
chitosanase, lysozyme and papain[84,85]. The enzyme lysozyme is known to degrade 
chitosan in-vivo through hydrolysis of the acetylated residues, with the rate of 






Figure 1-6 Schematic illustration of chitosan’s versatility. At low pH (< 6), chitosan’s 
amine groups are protonated conferring polycationic behaviour to chitosan. At higher 
pH (above about 6.5), chitosan’s amines are deprotonated and reactive. Also at higher 
pH, chitosan can undergo inter-polymer associations that can lead to fibre and network 
(i.e. film and gel) formation[79]. 
Chitosan is used in many applications, however its solubility in only a few dilute acid 
solutions limits the ability to vary its mechanical properties. In order to increase 
chitosan’s usage in many applications, chemically-modified chitosan derivatives have 
been synthesized and reported[87]. For example, salicylic acid-grafted chitosan 
oligosaccharide nanoparticle has been synthesised for Paclitaxel (anti-cancer drug) 
delivery[88]. 
The interest in chitosan for drug delivery applications arises mainly from the fact that 
this natural polysaccharide allows for the production of biocompatible and 
biodegradable structures. Chitosan has been found to be non-toxic[58] and is an FDA 
approved food additive. Biocompatibility, biodegradability, and the ability to impart a 
positive charge allowing it to interact with negatively charged glycosaminoglycans 
present in the extracellular matrix, are some of the advantageous properties of this 
polymer in drug delivery systems[89]. Moreover, avoiding the need to use hazardous 
organic solvents make chitosan a suitable choice for fabricating particles since it is 
soluble in aqueous acidic solutions[90]. 
Chitosan-based structures have been widely utilised in the delivery of active agents 
and drugs to ocular systems[91], protein/peptides for nasal delivery [92–95], and anti-
cancer drugs for targeted cancer therapy[96–98]. Chitosan-coated super-paramagnetic 




and loaded with the drug Bortezomib (Velcade) by Unsoy et al.[99] This study reported 
that the pH-responsive magnetic targeting of Bortezomib was more efficacious than 
free drug treatment. Moreover, targeted delivery of Bortezomib reduced the frequency 
of drug administration by lowering the required amount of drug dosed. The use of 
chitosan in this nanoparticle helped to modify the surface properties of the magnetic 
core structure and improved the biodegradation profile[100]. 
1.4.2 Alginate 
Alginic acid, (also called algin or Alginate) is derived from brown algae 
(Phaeophyceae), including Laminaria hyperborea, Laminaria digitata, Laminaria 
japonica, Ascophyllum nodosum, and Macrocystis pyrifera[101]. Alginate is a linear, 
unbranched polysaccharide composed of monomers of β-D Mannuronic acid (M) and 
its C-5 epimer α-L-guluronic acid (G) residues covalently linked by (1-4) glycol 
bonds[102] (Figure 1-7). Addition of alcohol to alginic acid and followed by sodium 
carbonate, converts the alginic acid into sodium alginate. The viscosity of alginate 
solutions vary widely depending on the molecular weight of the polymer which can 
range from 80 kDa to 290 kDa[103]. Alginic acid is sparingly soluble in water, soluble 
in alkaline solutions but insoluble in most organic solvents. It is able to absorb 200–
300 times its weight in water. The solubility of alginic acid depends on the presence 
of anionic groups within the polysaccharide. Sodium alginate is slowly soluble in cold 
water, resulting in viscous solutions. However, it is insoluble in alcohol and organic 
solutions. On the other hand, calcium alginate is practically insoluble in water and 
organic solvents but soluble in sodium citrate[104]. 
 
 




Alginate gels cross-linked by Ca2+can be degraded by removal of Ca2+. Removal of 
Ca2+ can occur by the use of either a chelating agent such as ethylene glycol-bis (-
amino ethyl ether)-N, N, N’, N’-tetra acetic acid (EGTA), citrate, and phosphate or by 
the presence of a high concentration of ions such as Na+ or Mg2+. This process 
decreases the cross-linking of the gel and therefore gels are undermined. Alginate gels 
also degrade and precipitate in 0.1 M phosphate buffer solution forming a calcium 
phosphate precipitate, releasing entrapped materials within the gel[106]. 
Alginate gels have been widely used as biomaterials due to their biocompatibility 
which was studied by injecting calcium alginate into kidney capsules of rats.[107]. 
Alginate gels have also been used as tissue engineering scaffolds, models for 
extracellular matrices and drug delivery vehicles[108]. The advantages of alginate as a 
matrix for immobilisation or encapsulation of drugs, bioactive molecules or controlled 
release are its biodegradability, readily availability, non-toxicity, and water solubility. 
The capability of sodium alginate to be cross-linked with a variety of cross-linking 
agents is one of the important advantages of alginate which is used to delay the release 
of some drugs[104]. Alginate can be simply altered via chemical and physical reactions 
to achieve derivatives with different structures, properties, and therefore applications. 
Alginate can also be prepared in three-dimensional scaffolding materials such as 
hydrogels, microspheres, nanoparticles, sponges, foams and fibres[105]. For example, 
hybrid alginate/CaCO3 nanoparticles prepared by Wu.J et al.
[109] were capable of 
sustained delivery of a hydrophilic drug (doxorubicin hydrochloride, DOX) and a 
hydrophobic drug (paclitaxel, PTX) into tumour cells. The presence of alginate could 






Polycaprolactone (PCL, 80 kDa, Ref. 440744 Sigma-Aldrich) pellets, and Chitosan 
(medium molecular weight of about approx. 450 kDa, Ref.448877 Sigma-Aldrich with 
degree of deacetylation of ca. 80.0%) and alginic acid sodium salt from brown algae 
(medium molecular weight), Toluidine blue O (also known as toluidine blue or TB), 
calcium carbonate anhydrous, glucono-δ-lactone (GDL), and Phosphate buffered 
saline (PBS, pH 7.4) were purchased from Sigma–Aldrich (Australia). Acetic acid, 
acetone, methanol, ethanol, isopropanol, chloroform, N,N-dimethylformamide 
(DMF), tetrahydrofuran (THF), Dichloromethane (DCM) sodium hydroxide pellets 
were supplied from Ajax Finechem (Australia). Calcium chloride dihydrate from 
Chem-supply and genipin from challenge bioproducts (Taiwan) were purchased.  
2.1 Fabrication of wet-spun fibre 
In this section, the process used in this work for fabricating the wet-spun fibres is 
explained. It consists of multiple stages that are detailed as follows. 
2.1.1 Spinning solution preparation 
PCL spinning solutions were prepared by dissolving PCL pellets in the desired solvent 
(acetone, THF, Dichloromethane, and chloroform) over 24 h by constant stirring. PCL 
pellets were dissolved in DMF at 50 ºC with constant stirring to obtain PCL spinning 
solution. Spinning solutions were prepared in each solvent with concentration various 
from 5 to 20% w/v. 
Chitosan solutions (3% (w/v)) were prepared in water containing 2.5% (v/v) acetic 
acid. The mixture was stirred at 50 ºC for 24 h.  
Alginate (3.5% (w/v)) was made by adding the alginate sodium salt powder into water 
and stirring for 24 h at 50 ºC.   
In the fabrication of the coaxial fibres, three solutions were prepared; alginate, chitosan 
(as a hydrogel core), and PCL as the sheath. Alginate (3.5% w/v) was prepared in 
water, whilst 3% w/v chitosan solution was prepared by mixing medium molecular 
weight chitosan with deionized water and 2.5% v/v acetic acid. PCL (15% (w/v)) 
dissolved in DMF were used as the sheath. Spinning solutions were placed in a 10 mL 
syringe held at RT (room temperature) for a period of time prior to spinning in order 




2.1.2 Coagulation bath preparation  
PCL coagulation baths were selected depending on the solvents of PCL. Water used 
as a coagulation bath for wet spinning of PCL dissolved in DMF which is labelled in 
this thesis as PCL-DMF/water (PCL-solvent/non-solvent). Coagulation bath of PCL 
dissolved in acetone was water/ethanol 70/30 v/v which is labelled PCL-
acetone/water-ethanol 70/30 v/v. Non-solvent used for spinning of PCL dissolved in 
DCM and chloroform was methanol/water 70/30 v/v which is shown in this thesis as 
PCL-DCM/ MeOH-water 70/30 v/v and PCL-chloroform/MeOH-water 70/30 v/v. 
1M NaOH in 10% v/v EtOH was used as coagulation bath of chitosan and 2% w/v 
CaCl2 in 20% v/v EtOH coagulation bath used for wet-spinning of alginate fibres.  
2% w/v CaCl2 and 1M NaOH coagulation bath was used to spin PCL/Alg and PCL/CS 
coaxial fibres, respectively.  
Washing processes were performed during the spinning and after collecting the fibres. 
Fibres were washed with 70% v/v EtOH then dried on the collector at room 
temperature. The washing process was performed after collecting all the fibres on 
collector for second time before drying. 
2.1.3 Fibre spinning 
The coaxial wet-spinning setup was similar to that used for conventional wet-spinning, 
however, two syringe pumps (KD Scientific KDS100) and coaxial spinneret were 
used. The prepared spinning solutions were delivered by syringe using syringe pumps 
and the syringes connected to the coaxial spinneret. The spinneret was placed into the 
coagulation bath in a way that the nozzles were completely immersed in the 





Figure 2-1 Image of coaxial wet-spinning set-up which two syringes on two syringe 
pumps connected to spinneret in the coagulation bath. 
Fibres extruded from the end of the spinneret were either washed and collected or 
stretched by a stretching roller to obtain improved mechanical properties. Figure 2-2 
shows the schematic image of the co-axial wet-spinning setup. The collector speed 
was adjusted to 35 rpm in all spinning methods. Syringe pumps were set to a defined 
flow rate for both core and sheath. The flow rate varied based on the polymer 
properties. Table 2-1 and Table 2-2 show the different flow rates that were utilised 
for the fabrication of different types of fibres. 
 
Figure 2-2 A schematic image of co-axial wet-spinning setup. a) Syringe pumps were 
used to pump b) spinning solutions at a specific flow rate into the spinneret placed in 
the c) coagulation bath. The fibre formed in the bath was stretched by a stretching 





Table 2-1 Flow rate of different solutions used for fibre spinning 
Fibres Conc. (% w/v) Coagulation bath Flow rate (mL.h-1) 
PCL 15 Water 10 
PCL hollow 15 Water 15 
Alginate 3.5 





















































2.1.3.1 Coaxial Spinneret 
A stainless steel pre-designed coaxial spinneret was used to spin coaxial fibres. Two 
syringes were connected to the spinneret ports via teflon tubes. The spinneret consisted 
of an inner nozzle and outer nozzle ( Figure 2-3 (c)) with two ports which allowed for 
extrusion of two fluids into a coagulation bath[40]. Figure 2-3 (a and b) show the 
spinneret and nozzle with measured diameters. The inner nozzle was positioned 
exactly in the centre and was adjusted by modulating the bolts on the spinneret. This 





Figure 2-3 a) Microscopic image of spinneret’s nozzle, and b) photo of the spinneret, 
and c) cross-section of coaxial spinneret (blue port: sheath, and pink port: core). 
2.2 Characterisation of as-prepared fibres  
In order to characterise the fibres properties, different methods as listed in the 
following sections were used. They are briefly explained in this section. 
2.2.1 Differential Scanning Calorimetry 
Differential Scanning Calorimetry (DSC) analysis was performed on a DSC Q100, TA 
Instruments. The constant heating rate of 10 ºC min-1 was applied on fibres (5-10 mg) 
packed in aluminium pans (internal volume of 10 µL) under a nitrogen flow. The 
samples were first heated to above the melting temperature of the polymer (100 ºC) 
and held at that temperature for 5 min to erase the thermal history, then cooled to 0 °C 
and reheated again to 100 °C. The melting temperature (Tm) and the melting enthalpy 
(ΔH) of PCL were determined from the first and second heating scans. The 
crystallinity degree (Xc) can be calculated by applying equation (1)




 ∗  100 % 
(1) 
 
 where ΔH0m is the melting enthalpy of 100% crystalline PCL, which is 139.5 Jg
-1[111] 
and the sample melting enthalpy, ΔHm, was determined by integrating the areas (J/g) 





2.2.2 Stereo microscopy analysis 
The average PCL fibre diameter was determined using a LEICA m205A stereo 
microscope. Fibre diameters were measured at least 5 times on four fibres of each type 
in stereomicroscope image. The average diameters are reported as the average ± 
standard deviation. The morphology of cross-section of coaxial fibres was observed in 
liquid nitrogen by optical microscope. Sample holders were placed in petri dishes with 
liquid nitrogen to avoid sample dehydration while imaging by microscope.  
2.2.3 Scanning electron microscopy (SEM) analysis 
LVSEM (low vacuum scanning electron microscopy) in a JSM-6510LV device was 
used in order to analyse overall surface, cross-section morphology, and diameter 
developed fibres. Analysis was performed at an accelerating voltage of 15 kV at 
magnification between 100x and 10000x. The sample preparation for SEM analysis is 
as follows for different samples: Dry samples were prepared by cutting them in liquid 
nitrogen using a sterile surgical blade and coated with platinum while wet fibres were 
prepared by freezing samples in liquid nitrogen for 45 seconds and then cutting with 
blade and immediately placed in LV-SEM chamber. Cross-section samples were not 
coated with platinum.  
2.2.4 Mechanical Properties Test 
Tensile testing was carried out using EZ-L Tester from Shimadzu, Japan with a 10 N 
load cell, using a crosshead speed (V1) of 5 mm/min and a gauge length of 10 mm at 
room temperature. Chitosan and alginate samples were mounted on an aperture card 
(1.0 cm length frame) with super glue. Average Young's modulus and ultimate tensile 
stress were determined after testing four times for each type of fibre. Young’s modulus 











2.2.5 In vitro Toluidine Blue (TB) release study 
The profile of TB release from wet-spun fibres was determined by collection of TB 
aliquots in phosphate-buffered saline PBS at varying time points (0-300 h). The release 
medium was collected by micropipette at specific time points and replaced with the 
same volume of fresh PBS (total volume of 1 mL). Fibres were placed in 1.5 mL vials 
with 1 mL of PBS in U-shape to avoid contacting the fibre ends with the medium. 
Vials containing fibre and PBS were incubated at 37 °C and spun at 50 rpm. The 
amount of released TB was determined using a Shimadzu UV 1601 spectrophotometer. 
In order to construct the absorption/concentration calibration curve, a standard curve 
of TB in PBS (0.01µg/mL to 10 µg/mL) was generated and the absorbance of TB at 
its λmax 630 nm (by UV-Vis spectroscopy) was monitored.  
The TB loading efficiency was estimated by placing 1 cm of fibre containing TB in 
PBS for 2 months. TB release data were reported as a percentage of release (Mt) 
relative to total TB loading (Mtot).  
2.2.6 Rheology  
Gelation study was conducted with a rheometer (TA Instruments AR-G2) using a 
cone-plate geometry (cone angle 2º, diameter 40mm, and truncation 55µm). Liquid 
samples were transferred into the cell immediately after mixing (t = 0). Time sweeping 
procedure was used to test samples and measurement stopped at 500 min. Storage 
moduli G′ and loss moduli G′′ were monitored as a function of time at a 1 Hz frequency 
and a 0.1% strain under constant temperature at 15 °C. Gelation time was determined 





3 RESULTS AND DISCUSSION 
3.1 PCL solvent selection 
The solubility of PCL was tested in a range of organic solvents as shown in Table 3-1. 
PCL was found to be soluble in DMF and acetone at 50 °C; DCM, chloroform, and 
THF at room temperature, but insoluble in EtOH, MeOH, and IPA.  
Table 3-1 Solubility of PCL in a range of solvents 
Solvent Type PCL solubility Temperature 
N,N-Dimethylformamide 
(DMF) 
Yes 50 °C 
Acetone Yes 50 °C 
Tetrahydrofuran (THF) Yes RT 
Dichloromethane (DCM) Yes RT 
Chloroform Yes RT 
Ethanol (EtOH) No RT 
Methanol (MeOH) No RT 
Isopropanol (IPA) No RT 
Water No RT / 50°C 
 
Due to the limited solubility of PCL in some solvents, water/ethanol (70/30 v/v), 
methanol/water (70/30 v/v), and water were used as non-solvents for PCL dissolved 
in DMF, acetone, DCM, and chloroform respectively[112] (Table 3-3). This 
solvent/non-solvent interaction was critical to induce precipitation of the injected PCL 
in order to form the fibre. 
3.2 PCL concentration selection 
Fibre “spinnability” is a function of the PCL solution injection flow rate, PCL 
concentration, and solvent/non-solvent system. Hence, a systematic study was 
performed to find out the effect of spinning conditions on spinnability of PCL solutions 
in order to optimise wet-spinning conditions. Different concentrations of PCL (5 to 




chloroform and spun into water, water/EtOH (70/30 v/v), MeOH/water (70/30 v/v), 
and MeOH/water (70/30 v/v) at a flow rate of 10 mL.h-1 (Table 3-2).  
According to results presented in Table 3-2, PCL solutions of ≤10% w/v concentration 
were not suitable for wet-spinning since they produced fibres which were non-uniform 
in diameter and short in length. This was most likely due to the visually low viscosity 
of PCL solutions at this concentration. When the concentration was increased to 20% 
w/v it was also observed that fibres were not readily spun when PCL solutions were 
prepared using DMF, acetone, and DCM/co-solvent solutions, resulting in the fibres 
exhibiting lumps which may be due to the very visually high viscosity of these PCL 
spinning solutions. However, 20% w/v PCL dissolved in chloroform was shown to 
have a suitable viscosity for successful spinning, producing uniform fibres. From the 
data presented in Table 3-2, it appears that a PCL concentration of 15% w/v PCL 
prepared in DMF, acetone, and DCM solvents, resulted in formation of continuous 
fibres. PCL (15% w/v) dissolved in chloroform was not spinnable, therefore solutions 




Table 3-2 Spinnability of PCL in different solvents by varying the PCL concentration. 
(Non-solvent of DMF: water, acetone: water/EtOH (70/30 v/v), DCM: MeOH/water 
(70/30 v/v), and chloroform: MeOH/water (70/30 v/v) 










Acetone Yes (slow production) 






Dichloromethane (DCM) Yes (slow production) 
Chloroform Yes (non-uniform) 
20 N,N-Dimethylformamide 
(DMF) 
Yes (Lump formation) 
Acetone Yes (Lump formation) 
Dichloromethane (DCM) Yes (Lump formation) 







3.3 PCL Non-solvent Selection 
Different types of non-solvents were examined in order to optimize spinning 
conditions. Table 3-3 lists non-solvents used to wet-spin PCL fibres in various 
solvents. From the results, PCL-DMF/water (PCL-solvent/non-solvent), PCL-
acetone/water-EtOH (70/30 v/v), PCL-DCM/MeOH-water (70/30 v/v), and PCL-
chloroform/MeOH/water (70/30 v/v) were selected as desirable solvent/non-solvent 
systems. 
Table 3-3 Spinnability of PCL solutions at solvent/non-solvent systems. (PCL 
concentration: 15% w/v) 










































3.4 Effect of solvent/non-solvent selection on the morphology of fibres 
There were differences in the diameters of fibres produced using three different 
solvents and a constant PCL concentration of 15% w/v, as shown in Figure 3-1. The 
diameter of fibre is influenced by the solidification rate; due to acetone having a higher 
volatility than DMF, solvent extraction occurs quickly, resulting in a higher mass 
transfer rate which leads to a decrease in the flow rate of the jet into the coagulation 
bath and consequently fibres with a larger diameter are formed[113]. Wet spun fibres 
produced from a DMF solution have a higher coagulation rate due to the rapid mass 
transfer which occurs between DMF and water, resulting in fibres with a larger 
diameter (479.7 ± 4.6 µm). However, wet-spun fibres obtained from an acetone 
solution have a lower coagulation rate compared to DMF, therefore fibres having a 
smaller diameter were formed (326.5 ± 3.3 µm). In the case of wet-spun fibres from a 
DCM solution, the mass transfer was very slow. Therefore, the fibres were maintained 
in the coagulation bath for a period of time in order to complete the solidification 
process. Consequently, wet-spun PCL fibres produced from DCM have the smallest 
diameter compared with the other fibres (205.0 ± 2.6 µm). Figure 3-2 shows the 
optical images of fibres facilitated to measure the average diameter of each fibre. PCL 
dissolved in chloroform was omitted since it had a different concentration compared 
to the above prepared samples which had diameters of 161.3 ± 47.4 µm. In addition, 
the wet-spun PCL fibres obtained from chloroform were non-uniform, whereas those 
from the above-mentioned fibres were (as observed from the optical images and the 






Figure 3-1 The effect of solvent used to form a 15% w/v PCL solution and coagulation 
non-solvent on PCL fibre diameter. PCL–DMF/water and PCL-acetone/water-EtOH 







Figure 3-2 Optical microscopic images of fibres, a) PCL-DMF/water, b) PCL-
acetone/EtOH-water, c) PCL-DCM/MeOH-water and d) PCL-chloroform/MeOH-
water. 
Scanning Electron Microscopy (SEM) was used to study the effect of solvent/non-
solvent on the morphology of PCL fibres. Figure 3-3 shows the effect of solvents and 
coagulants on the cross-section of fibres. These fibres are circular in their shape, and 
their level of porosity differs significantly depending on the solvent in which they are 
dissolved. For example, PCL dissolved in DMF and water (used as non-solvent) had 
large and longitudinal pores, however PCL fibres with methanol/water non-solvent 
showed a smoother cross-section (with a few circular pores created due to either the 
presence of bubbles in solution or from solvent evaporation during the phase 
inversion). Evaporation of solvent from the fibre and solidification of the dissolved 





solution and gradually propagates towards the centre of the fibre[114]. Coagulant, 
solvent, and coagulation rate are the most important factors in determining fibre 
morphology in the wet-spinning process. This is most likely due to the difference in 
the mass transfer rate of solvent and coagulant during the coagulation process. A faster 
transfer rate between the solvent and non-solvent results in a fibre with a porous 
structure, whereas a slower transfer rate gives fibres with a denser structure[115]. The 
coagulation rate in PCL fibres with DMF as solvent and water as non-solvent was high 
with the fibre formed with an initial skin layer followed by the formation of the fibre 
itself. The large porous PCL fibres formed in DMF illustrates this finding (Figure 3-3 
(a)). However, the coagulation rate in PCL dissolved in acetone was not as rapid as 
PCL in DMF, therefore, a fibre having a smaller porosity was formed during the 
coagulation process (Figure 3-3 (c)). PCL fibres dissolved in DCM or chloroform had 
the slowest coagulation rate in this study. These fibres remained in the coagulation 
bath for a while in order to obtain solid fibres, resulting in fibres with an irregular and 
denser structure as shown in Figure 3-3 (e and g). 
The fibre cross section is determined by the mass transfer between the solvent and 
non-solvent[24]. With the same injection flow changing the solvent/non-solvent system 
has a significant impact on the fibre diameter. A lower solvent/non-solvent mass 
transfer ratio generates fibres with circular cross-section fibres. For example when the 
mass transfer rate (∆k) of the solvent is less than that of the coagulant (∆k < 0), the 
filament swells and a circular cross section can be observed.  
At a higher solvent/non-solvent mass transfer ratio (∆k > 0), the cross-section depends 
on the mechanical behaviour of the coagulated layer. A soft layer results shrinks 
leading to a circular cross section. In contrast, a rigid surface layer may fail leading to 
a noncircular and irregular shape[116]. A porous cross-section is an advantage for drug 
release. Hence PCL dissolved in DMF and acetone with porous structure could be 






Figure 3-3 SEM images of wet-spun PCL fibres in dry state. a) cross-section of 15% 
w/v PCL-DMF/water, b) surface of 15% w/v PCL-DMF/water, c) cross-section of 
15% w/v PCL-acetone/water-EtOH (70/30 v/v), d) surface of 15% w/v PCL-
acetone/water-EtOH (70/30 v/v), e) cross-section of 15% w/v PCL-DCM/MeOH-
water (70/30 v/v), f) surface of 15% w/v PCL-DCM/MeOH-water (70/30 v/v), g) 
cross-section of 20% w/v PCL-chloroform/methanol-water (70/30 v/v), h) surface of 




3.4.1 Mechanical Properties of PCL fibres 
The effect of solvent/non-solvent coagulation systems on the tensile properties of PCL 
fibres using three different solvents was investigated. Figure 3-4 shows the stress-
strain curves for PCL wet-spun fibres under different solvent/non-solvent conditions. 
The mechanical properties of wet-spun PCL fibres in different solvent/non-solvent 
systems were characterized by an initial linear region at low values of strain, followed 
by two further regions of varying stiffness. Since PCL is a flexible fibre, the initial 
stiffness response is not shown in the stress-strain curve. A distinct orientated, fibrillar 
morphology was produced at high strain which indicated a high degree of structural 
deformation and alignment induced by the process of drawing. The major influence of 
solvent/non-solvent on the tensile properties of wet-spun fibres is shown in Figure 
3-5. PCL wet-spun fibres produced in DMF as solvent and water as non-solvent had 
the lowest modulus of 18.2 ± 1.2 MPa, whereas PCL wet-spun fibres produced in 
DCM solvent and methanol/water as non-solvent had the highest modulus of 214.9 ± 
55.1 MPa (P = 0.0004). PCL fibres produced in acetone as a solvent and water/ethanol 
as non-solvent gave 98.9 ± 14.3 MPa Young’s modulus. The ultimate tensile strength 
of fibres was also at its highest 112.1 ± 12.4 MPa when DCM was used as a solvent 
for PCL and methanol/water as non-solvent and at its lowest 1.2 ± 0.3 MPa in the case 
of DMF/water solvent/non-solvent system (P < 0.0001). In the case of acetone as the 
solvent for PCL fibres and water/ethanol as non-solvent, the ultimate tensile strength 
of fibres was 8.78 ± 2.4 MPa. Changing the solvent/non-solvent system also had a 
slight effect on the elongation at break of fibres resulting in highest elongation at break 
548.4 ± 178.3% in the case of acetone as the solvent for PCL wet-spun fibres and 
lowest elongation break of 325.1 ± 178.3% for PCL wet-spun fibres produced in DCM 
solvents (P = 0.1269). PCL wet-spun fibres in DMF/water solvent/non-solvent system 
had 463.4 ± 117.4% elongation at break. 
The Young’s modulus of wet-spun fibres are influenced by the mass transfer rate 
between the solvent and non-solvent[116]. A higher mass transfer results in lower 
structural ordering and therefore lower values of Young’s modulus. In contrast, tensile 
strength and elongation at break at higher strains depends on the formation of porous 
or dense structure of the fibre. Consequently, PCL fibres produced in DMF/water 
solvent/non-solvent systems have the largest mass transfer and therefore lowest 




of fibre. On the other hand, formation of rigid layers of fibre in DCM solvent and 
methanol/water non-solvent raises the modulus of fibres. Production of denser fibres 
resulted in an increase in tensile strength and decrease in elongation at break. 
The results obtained demonstrate that fibres generated from PCL in DMF could 
potentially be used in tissue engineering applications since they have a lower Young’s 
modulus value and soft tissues (muscle, nerves, and blood vessels) also exhibit 
significantly lower Young’s modulus values. 
 
Figure 3-4 Stress-strain curve for tensile tests on PCL fibres spun in different 
solvent/non-solvent system (15% w/v PCL-DMF/water, PCL-acetone/water-ethanol 
(70/30 v/v), and PCL-DCM/methanol-water (70/30 v/v)). Inset: stress-strain curve for 






Figure 3-5 Effect of solvent/non-solvent systems on mechanical properties of 15% 
w/v PCL-DMF/water, PCL-acetone/water-EtOH (70/30 v/v), and PCL-
DCM/MeOH/water (70/30) fibres: a) Young’s modulus, b) ultimate tensile strength, 










3.5 Thermal properties of PCL fibres 
The PCL fibres which exhibited the best properties (i.e. those dissolved in DMF and 
acetone) were further characterised by thermal analysis (Figure 3-6). The thermal 
characteristics of these wet-spun fibres were compared with those of PCL pellets, 
shown in 
Table 3-4. Using the enthalpy values from the melting peaks, the degree of 
crystallinity of the PCL fibre was calculated using Equation (1). The samples were 
heated to above the melting temperature of the polymer (100 ºC), then cooled to 0 °C, 
and then reheated again to 100 °C. The first stage of heating was used to observe any 
effect the processing method had on development of the PCL structure. The melting 
temperature of PCL in acetone was lower than that for pure PCL and PCL in DMF. A 
possible reason could be due to the growth of the lamella thickness or increase in the 
Gibbs free energy. 
The Tm (melting temperature) remained fairly constant over the heating/cooling 
processes, however, slight increases in the level of crystallinity of PCL fibres suggests 
a formation of crystalline lamellae during dissolution and the wet-spinning process. 







Figure 3-6  Differential scanning calorimetry curves of PCL fibres produced with two 
different solvents (DMF and acetone) and non-solvents (water and water/EtOH 
(70/30)) compared with PCL pellets. The process of wet-spinning generally has a 
slight effect on the crystallization temperature of the PCL. 
Table 3-4 Thermal properties of wet-spun PCL fibres 








ΔHm (J/g) Crystallinity 
(%) 
PCL pellets 60.2 59.7 58.9 42.2 
PCL fibre in 
acetone 
59.9 58.5 76.3 54.7 
PCL fibre in 
DMF 






3.6 Wet-spinning of hydrogel fibres 
3.6.1 Chitosan Fibres  
Chitosan (2-4% w/v) of a medium molecular weight was prepared in water/2.5% v/v 
acetic acid at varying concentrations. The acid protonates the free amine group  present 
in chitosan, making it soluble in weakly acidic solutions (pH ≤5.0) [117]. 
3.6.1.1 Wet-spinning of chitosan fibres 
Chitosan fibres can be formed using both the rotary and horizontal coagulation 
systems, however only the rotary system was explored in this work (Figure 3-7). This 
method was chosen since it consumes less non-solvent in comparison with the 
horizontal procedure.  
It is necessary to use a strong alkaline solution to form chitosan structures; under such 
conditions chitosan is deprotonated, making it insoluble, and consequently coagulation 
occurs. Therefore, a solution of 1M NaOH and 10% v/v EtOH was used in the 
coagulation bath (with a collecting speed of 30-60 rpm). EtOH was used to accelerate 
the coagulation process by dehydrating the chitosan. 
 
 
Figure 3-7 Schematic image of rotary coagulation bath. 
The spinnability of chitosan at various concentrations, under the same injection flow 
rate was tested. At a concentration of 3% w/v it was possible to successfully spin and 
collect chitosan fibres continuously. However, at 2% w/v, fibre formation was slow, 
resulting in a dried fibre with poor mechanical properties which could not be collected 




highly viscous and difficult to spin to form a continuous fibre. Table 3-5 compares the 
spinnability of chitosan at various concentrations spun into NaOH/EtOH. 
Table 3-5 Comparison of spinnability of chitosan at constant flow rate of 25 mL.h-1. 
Chitosan Conc. 
(%w/v) 
Injection Flow Rate 
(mL.h-1) 
Spinnability 
2 25 Yes (slow production) 
3 25 Yes 
4 25 Yes (bumpy) 
 
Figure 3-8 shows the optical image of 3% w/v chitosan fibre after drying at room 
temperature. The diameter of the fibre in dry state is 193.6 ± 6.1 µm. Upon hydration 
in water the fibre diameter increased to 811.3 ± 12.2 µm. 
 
Figure 3-8 Optical image of 3% w/v chitosan wet-spun fibre (25 mL.h-1 flow rate). 
3.6.1.2 Morphological properties of chitosan wet-spun fibre 
Scanning electron microscopy (SEM) was used to determine the morphology of 
chitosan fibres in both the wet and dry state. It was obvious that chitosan has a smooth, 
uniform cross-section and surface area (Figure 3-9 (d and e)) in the dry state. 




chitosan fibre in hydrated state with a smooth surface area. Analysis of fibre 
morphology in the wet state must be carried out quickly as dehydration can occur while 
the sample is in the vacuum chamber. Micrographs of chitosan cross-section 
demonstrate a porous fibre structure filled with water in the wet state and smooth and 
dense structure after dehydration[118]. 
 
Figure 3-9 SEM image a) cross-section of hydrated 3% w/v chitosan wet-spun (inset 
higher magnification of cross-section of hydrated 3% w/v chitosan), b) surface of 3% 
w/v chitosan in the hydrated state, c) cross-section, and d) surface of  3% w/v chitosan 
in dry state. Fibres spun in 1M NaOH in water/ethanol 90/10 v/v coagulation bath. 
3.6.1.3 Mechanical Properties of chitosan fibres 
The Young’s modulus of 2% w/v and 3% w/v chitosan fibres were studied using a 
standard tensile test. A slight difference in the Young’s modulus was observed when 
the concentration of chitosan was increased; at 2% and 3% w/v concentration levels, 




in the Young’s modulus confers a decrease in fibre flexibility resulting in a more brittle 
chitosan fibre.  
Figure 3-10 outlines the difference in the stress-strain curve of chitosan fibres formed 
from two different concentrations at a constant spinning condition. Chitosan (3% w/v) 
wet-spun fibres exhibited a higher elongation at break (6.1 ± 0.8 %) compared with 
2% w/v chitosan which had 3.9 ± 0.3% elongation at break. Elongation at break 
expresses the change of final and initial length of fibre after breakage and can be 
increased by increasing the chitosan concentration.  
 
Figure 3-10 Stress-strain curve obtained from tensile tests of 2% w/v and 3% w/v 
chitosan fibres 
3.6.2 Alginate Fibres 
3.6.2.1 Wet-spinning of alginate fibres 
A rotary bath (Figure 3-7) containing 2% w/v CaCl2 in 20% v/v EtOH was used to 
spin alginate fibres. EtOH was selected to accelerate the coagulation process by 
dehydrating the alginate.  
Calcium chloride (CaCl2) is one of the most commonly used agents to cross-link 




options for cross-linking. Due to their lower solubility in water at neutral pH, they can 
reduce the gelation rate. The process is explained below. 
Two G blocks of the polymer can be cross-linked with divalent cations (e.g., Ca2+or 
Ba2+)[108].  An alginate solution can be mixed with CaCO3, followed by addition of 
Glucono-δ-lactone to the mixture, resulting in the disassociation of Ca2+ from the 
CaCO3 by lowering the pH. The released Ca
2+ then initiates the gelation of the alginate 
solution at a slow rate[119]. 
 
Figure 3-11 In the presence of divalent calcium ions, the calcium chelates to the 
carboxylate ions. The result is a chain of calcium-linked alginate which forms a gel[120]. 
Different concentrations (0.5-3.5% w/v) of alginate solution were prepared by mixing 
alginic acid sodium salt (medium molecular weight) with de-ionized water and stirring 
the resulting mixture for 24 h at 50 ºC. The coagulation solution used was 2% w/v 
calcium chloride (CaCl2) which has been reported as a standard coagulation solution 
for alginate[120]. Using CaCl2 it was possible to form fibres from 1% to 3.5% w/v 
alginate.  Since a higher concentration of alginate is able to encapsulate a larger 
percentage of drug, 3.5% w/v of alginate was used for our studies described in this 
thesis. This concentration of alginate  was the upper threshold that facilitated formation 
of wet-spun fibres and it was used  in the formation of coaxial PCL/Alg fibres (section 
3.10.2)[121]. 
Alginate fibres were spun in a long bath using the injection flow rates of 5 mL.h-1, 15 




and dried at room temperature. Figure 3-12 shows the optical image of dry alginate 
fibre, and Table 3-6 shows that the diameter of 3.5% w/v alginate fibres increased 
with constant spinning by increasing the solution’s flow rate from 5 to 50 mL.h-1. 
 
 
Figure 3-12 Optical image of dry 3.5% w/v alginate fibre spun in 2% CaCl2 





Table 3-6 Effect of flow rate on diameter of 3.5% w/v wet-spun alginate fibre at dry 
state. 
Flow rate (mL.h-1) Fibre Diameter (µm) 
5 99.3 ± 0.6 
15 113.2 ± 1.7 
50 167.5 ± 1.4 
 
3.6.2.2 Morphological Properties of Alginate Fibres 
When a dehydrated fibre is rehydrated in an aqueous solution, the diameter of the fibre 
returns to the initial as-spun hydrated diameter. Figure 3-13 shows the 3.5% w/v 
alginate fibre in dry (a), rehydrated (b) states and demonstrating that the 3.5% w/v 
alginate wet-spun fibre has a smooth cross-section area when fully hydrated. It is clear 
that the shape of the cross-section is significantly varied during the dehydrating 
process. However, by rehydrating the fibre, the circular cross-section is regained as 
shown in Figure 3-13 (b). Alginate fibres like chitosan fibres have porous and spongy 
cross-sections filled with water in the wet state that has potential for future applications 
as a drug carrier[40] (Figure 3-13 b inset). 
 
Figure 3-13 SEM image of 3.5% w/v alginate fibre a) dehydrated, b) rehydrated state, 





3.6.2.3 Mechanical properties of alginate fibres 
The effect of injection flow rate on the mechanical properties of alginate fibres was 
studied. The mechanical properties of fibres produced from a solution of 3.5% w/v 
alginate formed at different flow rates (5-50 mL.h-1) is shown in Figure 3-14. 
Observation of stress-strain curves reveals that mechanical properties of fibres are 
affected by the spinning conditions. Young’s modulus values of these fibres was 
deduced from the initial most linear part of the curves (Figure 3-14). The young’s 
modules of the alginate fibres increased from 0.8 ± 0.1 GPa to 2.1 ± 0.1 GPa and 4.1 
± 0.7 GPa when the flow rate of alginate spinning solution was increased from 5 to 50 
mL.h-1, respectively. Moreover, the ultimate stress increased while elongation at break 
did not change significantly. 
 
Figure 3-14 Stress-strain curve of 3.5% w/v alginate fibre wet-spun in three different 
flow rates. 
The results of wet-spun fibres in different solvent and non-solvent, PCL-DMF/water 
appear to have improved properties in comparison with others. Moreover, these fibres 
are readily spinnable in water at a higher coagulation rate. Therefore, for coaxial fibres 
which will be discussed in the next section, PCL-DMF/water was utilised as a sheath 




3.7 Wet-spinning of Coaxial Fibres 
The next stage of the thesis presents the work undertaken to form coaxial 
PCL/hydrogel fibres. Prior to forming these coaxial fibres it was important to gain an 
understanding on how the PCL fibre forms by coaxial spinneret. Initially PCL hollow 
fibres were fabricated and characterised, followed by PCL/alginate and then finally 
PCL/chitosan coaxial fibre spinning and characterisation. 
3.7.1 PCL hollow fibres 
Preliminary studies of formation of hollow PCL coaxial fibres were performed prior 
to attempting to co-axially wet-spin PCL/CS and PCL/Alg coaxial fibres. The 
optimized coaxial wet-spinning method used to wet-spin these hollow PCL fibres is 
shown in Figure 2-2. To form such hollow fibres, the PCL solution was used as a 
sheath and water was used as the core. The hollow PCL fibres were wet-spun at a flow 
injection rate of 15 mL.h-1 and collected at a speed of 30 rpm. The fibres were dried in 
a vacuum oven for 24 h at 50 °C. The fibres were wet-spun by spinneret with the 
diameter of 1.309 mm as shown in Figure 3-15. The geometry of nozzle plays an 
important role in the morphology of the fibre. Any deformation or scratch on the wall 
of the nozzle may change the circular shape of the fibre to an irregular shape. 
 





3.7.1.1 Morphology characterization of hollow PCL fibre 
In order to obtain an appropriate fibre diameter and morphology, SEM and optical 
microscopy analyses was performed on the hollow PCL fibres. Fibres with a diameter 
of 1.3 ± 0.1 mm were obtained however through variation of uptake speed of the 
collector and flow rate the wall thickness of hollow fibres can be adjusted. By 
increasing the speed of collector, fibre diameter, as well as wall thickness, decreased. 
The total diameter of fibre reduced to 70.1 ±4.2 µm.  
As shown in Figure 3-16 (a), wall thickness of the hollow fibre was non-uniform. This 
was due to the core nozzle not positioned in the exact centre of the sheath. The 
spinneret used to wet-spin the fibre is shown in Figure 3-16 (b). 
SEM images showed that the cross-sectional area of the PCL hollow fibre was 
perfectly circular; the fibre holds the circular shape of the extrusion tip. The PCL 
hollow fibre was porous and a dense support layer between its inner and outer skin had 
been formed (Figure 3-17 (b)). A microporous morphology has been created on both 
sides  of the inner boundary. Since PCL fibre was in contact with coagulation bath at 
its inner and outer sides (Figure 3-17), a skin layer was formed at both sides. In 
contrast, the PCL solid wet-spun fibre (Figure 3-3) consists of outer skin (a dense 
layer) only, a boundary layer has not been created and the internal structure is porous. 
 
Figure 3-16 a) SEM image of hollow PCL wet-spun fibre by the co-axial wet-spinning 
method, and b) microscopic image of spinneret used to wet-spin PCL hollow fibre. 






Figure 3-17 SEM cross section image of a) PCL hollow fibre, and b) PCL hollow fibre 
wall with higher magnification. 
PCL hollow fibres were successfully wet-spun (injection flow rate of 15 mL.h-1). Wet-
spinning parameters such as spinneret adjustment, coagulation bath, washing bath, and 
injection flow rate were optimised to allow for the fabrication of continuous and 
uniform PCL hollow fibres. The SEM images of these fibres showed highly 
microporous structures. The following step involved replacing the water core with 
hydrogels to fabricate PCL/hydrogel coaxial fibres.  
3.7.2 PCL/Alg and PCL/CS Coaxial Fibres 
3.7.2.1 Wet-spinning of PCL/Alg and PCL/CS Coaxial Fibres 
PCL/Alg coaxial fibres were produced by using PCL and alginate solutions in 
individual syringes. Coaxial fibres were fabricated by the wet spinning process as 
shown in Figure 2-2. Different injection flow rates were used for both the core and 
sheath to obtain a desirable structure. In order to produce a continuous coaxial fibre, 
many parameters must be considered. The most important parameters are coagulation 
bath and flow rate of the injected solution. The selected coagulation bath must 
coagulate both the core and sheath simultaneously, which means that it is necessary 
that coaguation bath diffuses into the core in order to coagulate the inner spinning 
solution. Therefore, the morphology of the fibre should also be considered. In this 
study PCL has a porous structure (Figure 3-17) which allows the coagulation bath 
solution to diffuse into the core in order to coagulate the core material. As PCL 




coagulation bath solution. 2% w/v CaCl2 was usedas a coagulation bath for PCL/Alg 
coaxial fibres, since CaCl2 is a commonly used cross-linker for alginate, and PCL can 
be coagulated by water only. Figure 3-18 shows that unlimited lengths of fibre can be 
produced by coaxial wet-spinning. 
 
Figure 3-18 Photograph of unlimited continuous length of coaxial PCL/Alg fibre in 
the coagulation bath of 2% w/v CaCl2. Flow rate of core = 10 mL.h
-1, sheath flow rate 
= 10 mL.h-1. 
The applied injection flow rate was 10 mL.h-1 (core), and 10 mL.h-1 (sheath) for coaxial 
fibres However, different injection flow rates were applied to optimise the wet-
spinning condition in order to obtain reproducible coaxial fibres. 
Since the PCL fibres are not transparent it was difficult to ensure that the fibre 
contained hydrogel. Two different approaches were tried to better visualise the 
formation of a core in the PCL fibre. Firstly Toluidine Blue dye was used in the core 
solution (alginate). The colour due to the dye was obvious during the wet-spinning 
process, however, when the PCL fibre dried its core was not clearly visible through 
the surface of the fibre, it was only able to be seen from a cross-section of the fibre. In 
order to take optical images of the fibre to highlight the core clearly (Figure 3-19), a 
few drops of DMF (PCL solvent) were placed on the fibre, dissolving a thin layer of 
the sheath to reveal the core (Figure 3-19 (a)). The PCL/CS fibre did not contain the 





Figure 3-19 Optical microscopic surface images of a) PCL/Alg and b) PCL/CS co-
axial fibre. TBO (Toluidine Blue O) dye has been added to alginate in order to be 
easily visible, and cross-section images of c) PCL/Alg and d) PCL/CS wet-spun 
coaxial fibre immediately after spinning. 
The cross-section of coaxial fibres can be readily seen in the wet and dry state (Figure 
3-19 (c and d)). It must be noted that imaging must occur immediately after wet-
spinning in order to see the hydrated hydrogel core. To prevent the fibres from drying 
out they must be kept in PBS or water. Figure 3-20 shows the fibres that were kept in 
water for 30 min after spinning and clearly show the hydrogels swell when they absorb 






Figure 3-20 Optical microscopic images of a) PCL/Alg and b) PCL/CS wet-spun 
coaxial fibres immediately after spinning while stored in water for 5 min. Hydrogel 
absorbing water resulting in swelling and protrusion of the core. 
3.7.2.2 Morphological Properties of PCL/Alg coaxial wet-spun fibre 
The effect of flow rate on the morphology of PCL/Alg coaxial fibres was investigated 
at constant draw ratio by measuring the fibre diameter through SEM. Measuring the 
core diameter in SEM is inaccurate as dehydration occurs during the imaging process 
(Figure 3-24). Therefore, to measure the core diameter an optical microscope must be 
used as shown Figure 3-21. To image the coaxial fibres, they must be placed into 
liquid nitrogen immediately after spinning to avoid dehydration. Figure 3-21 shows 
optical images taken while the fibres were mounted on a specimen holder and placed 
into a petri dish containing liquid nitrogen. In this study, our focus was on sheath 
diameter (PCL), therefore SEM was the best choice for analysis. The results 
demonstrated that increased sheath flow rate yielded an increase in total fibre diameter 
(Figure 3-23). The total fibre diameter increased from 363.2 ± 56.1 µm to 534.5 ± 
74.2 µm and 596.3 ± 110.2 µm by an increase in flow rate of sheath from 10 to 30 and 
40 mL.h-1, respectively, at constant 10 mL.h-1 core flow rate. In contrast, increasing 
the core flow rate (at a constant sheath flow rate) did not significantly change the total 
fibre diameter, but  the diameter of sheath decreased. Due to the flexibility of PCL, it 
can be easily affected by the core flow rate and it becomes thinner by increasing the 
core flow rate. Figure 3-22 shows the effect of core flow rate on the diameter of the 
sheath. The sheath diameter decreased from 25.3 ± 0.6 to 3.6 ± 0.7 µm when the core 
flow rate increased from 10 to 20 mL.h-1 at a constant 10 mL.h-1 flow rate of the sheath 
and constant drawing ratio. Moreover, at a constant flow rate of 30 mL.h-1, the sheath 




from 100 to 200 mL.h-1. By increasing the flow rate of the core from 100 to 200 mL.h-
1 (at a constant sheath flow rate of 40 mL.h-1), the sheath diameter decreased from 58.4 
± 1.3 to 10.3 ± 1.9 µm. Table 3-7 summarises the above mentioned data.  
Table 3-7 Summary of the total and sheath diameters of fibres at various sheath and 
core flow rates 
PCL/Alg coaxial fibre 
Sheath flow 
rate 

















363.2  ± 56.1 
371.1 ± 48.3 
 
534.5 ± 74.2 
548.1 ± 3.4 
 
596.3 ± 110.2 
609.4 ± 99.7 
25.3 ± 0.6 
3.6 ± 0.7 
 
46.7 ± 2.2 
11.4 ± 1.7 
 
58.4±1.3 
10.3 ± 1.9 
 
Figure 3-23 illustrates the SEM images of coaxial PCL/Alg fibres produced at varying 
core and sheath flow rates. In summary, changing the flow rate during the wet-spinning 
process produces fibres with different diameters. To obtain fine fibres with diameters 
of 100-300 µm, a lower flow rate must be used. However, this results in the sheath 
having a larger diameter and in turn diffusion of the cross-linker (e.g., CaCl2) into the 
core becomes difficult. Therefore, another cross-linker was considered. Experiments 





Figure 3-21 Optical microscope cross-section images of a) PCL/Alg wet-spun fibre, 
and b) PCL/CS wet-spun fibre in liquid nitrogen immediately after wet-spinning. 
PCL (sheath) and Alg (core) fibres do not interact in coaxial fibres after the drying 
process (Figure 3-24(c)). This can be expected as PCL is hydrophobic, while alginate 
is hydrophilic. The surface charge may also be another factor as both PCL and alginate 
have a negative surface charge, or it may be due to the different shrinkages are obtained 
for PCL and alginate. When the coaxial fibre is rehydrated in PBS or water it returns 
to its initial structure. Figure 3-24 shows the PCL/Alg wet-spun coaxial fibre in the 






Figure 3-22 Effect of core flow rate on the sheath diameter at a constant drawing ratio 





Figure 3-23 SEM images of hydrated PCL/Alg wet-spun fibre with a) 40 mL.h-1 flow 
rate of Sheath and 100 mL.h-1 flow rate of core, b) 40 mL.h-1flow rate of sheath and 
200 mL.h-1 flow rate of core, c) Sheath flow rate: 30 mL.h-1 and core flow rate: 100 
mL.h-1, d) sheath flow rate: 30 mL.h-1 and core flow rate: 200 mL.h-1, e) sheath flow 
rate: 10 mL.h-1 and  core flow rate: 10 mL.h-1, and f) sheath flow rate:10 mL.h-1 and 






Figure 3-24 SEM image of PCL/Alg fibre in a) wet state, b) same PCL/Alg fibre after 
5 minutes in SEM chamber, and c) completely dry PCL/Alg fibre. 
3.7.2.3 Morphological Properties of PCL/CS Wet-spun Fibre 
The Effect of flow rate has been investigated on the morphology of PCL/CS wet-spun 
fibres by maintaining a constant sheath flow rate (25 mL.h-1) then increasing the core 
flow rate effect on the total diameter of fibre as well as sheath diameter were studied. 
Figure 3-25 shows the SEM image of PCL/CS fibres which core flow rate increase 
from 5 mL.h-1 (Figure 3-23(a)) to 15 mL.h-1 (Figure 3-25(b)).  The cylinder shape of 
the fibre is intact in the dry state. Moreover, the PCL fibre has not changed in dry 
condition however the chitosan hydrogel core appeared to attach to the inner wall of 
the PCL fibre, losing its fibrous structure under dehydration conditions. The fibre total 
diameter increased from 545.0 ± 19.5 µm to 597.0 ± 61.1 µm, however, the diameter 
of sheath (wall thickness) decreased from 93.6 ± 31.0µm to 68.9 ± 14.2 µm when the 
core flow rate increased from 5 to 15 mL.h-1 (constant sheath flow rate (25 mL.h-1)).  
From these results, it appears that a flow rate of 25/5 mL.h-1 of sheath/core is the ideal 
flow rate to obtain a fibre with a total diameter of 100-200 µm. Table 3-8 summarises 
the above mentioned data. 
Table 3-8 Summary of the total and sheath diameters of fibres at various sheath and 
core flow rates 
PCL/CS coaxial fibre 
Sheath flow 
rate 







545.0 ± 19.5 
 
597.0 ± 61.1 
 
93.6 ± 31.0 
 







Figure 3-25 SEM image of dry PCL/CS fibre, a) wet-spun with sheath flow rate of 25 
mL.h-1 and core of 5 mL.h-1 and inset higher magnification of interaction between 
chitosan and PCL and b) sheath flow rate: 25 mL.h-1 and core flow rate: 15 mL.h-1 in 
1M NaOH coagulation bath and inset higher magnification of chitosan attached to PCL 
wall. 
After drying, the chitosan fibre attached to the wall of the PCL fibre. However, in the 
case of a dry wet-spun PCL/Alg fibre (Figure 3-24 (c)) the alginate maintained its 
fibrous structure and completely detached from the PCL.  
To ensure that coaxial PCL/CS fibres maintain a fibrous structure in wet conditions, 
completely dry fibre was placed into PBS for 24 h. Figure 3-26 (a) shows the dry fibre 
and Figure 3-26(b) shows the fibre rehydrated for 24 h. It is clearly visible that the 
fibre returned to its initial structure. 
 
Figure 3-26 SEM image of PCL/CS wet-sun fibre in a) dry state and b) rehydrated 




3.7.2.4 Mechanical Properties of PCL/Alg and PCL/CS wet-spun fibres 
Mechanical properties of PCL/CS and PCL/Alg coaxial fibres have been studied in 
order to calculate Young’s modulus of fibres, primarily to examine the elasticity of 
fibres. In order to utilise fibres in future applications, fibres must be soft, flexible, and 
easy to handle; by lowering Young’s modulus softer fibres can be produced. The 
Young’s modulus of fibres was calculated from the linear part of the curve. The 
Young’s modulus of PCL/Alg wet-spun coaxial fibre was calculated to be 2.31 ± 0.38 
MPa and PCL/CS wet-spun fibres gave Young’s modulus of 0.66 ± 0.07 MPa. 
Young’s modulus values of coaxial fibres decreased significantly in comparison to 
solid individual fibres. Figure 3-27 (a and b) show the stress-strain curves of coaxial 
fibres; both graphs depict a sudden drop after approximately 40-80% strain. The first 
decrease in the stress/strain curve corresponds to breakage of the core (chitosan and 
alginate fibre), and due to the larger elongation at break of PCL fibres, second breakage 
of fibre shows PCL elongation at break. The PCL/CS coaxial fibres exhibited an 
increase in the first elongation at break from approximately 6.15% to 80%. This 
significant increase may be due to the change in fibre morphology in the coaxial state. 
The shape of the chitosan fibre in the coaxial state post drying changed from a circular 
fibrous structure to a hollow chitosan fibre. Moreover, after drying the chitosan fibre 
attached to the PCL fibre wall which is possibly due to a chemical interaction. 
However, the change of the first elongation at break in the PCL/Alg coaxial fibre in 
comparison to alginate solid fibre was negligible. This is expected as the PCL/Alg 
coaxial fibre became detached after drying. The fibre morphology was similar to the 
PCL hollow fibre with one alginate fibre within. The total elongation at break of 






Figure 3-27 Stress-strain curve of a) coaxial PCL/CS wet-spun fibres, and b) coaxial 
PCL/Alg wet-spun fibres. 
3.7.2.5 In-vitro Release Measurement of TBO from PCL/Alg and PCL/CS wet-spun 
fibres 
The release of TBO (Toluidine Blue O) from PCL/Alg and PCL/CS coaxial wet-spun 
fibres was performed in PBS (pH~7.4) at 37 °C by placing 4.0 cm of coaxial fibre 
containing dye within the core. The released PBS medium was collected by 
micropipette at specific time points and replaced with the same volume of fresh PBS 




(Toluidine Blue) at its λmax (630 nm). The established standard curve for determining 
TB concentration in PBS solution was y = 0.00268 + 0.03785*x and R2 = 0.99788 as 
shown in Figure 3-28. 
 
Figure 3-28 Calibration curve of TBO in PBS. 
The loading efficiency of TB per 1.0 cm was estimated by dissolving 1.0 cm length of 
fibre in PBS solution. The TB concentration was obtained by UV-Vis spectroscopy 
and cumulative TB release data plotted as a percentage of (Mt) release relative to the 
TB loading (Mtot). 
The release profile of TBO from loaded coaxial and solid fibres were plotted relative 
to time and are shown in Figure 3-29. The release was monitored for 3 weeks, however 
no additional TB was released from the fibre. Three samples from each fibre were 
examined and the curve obtained represented the average of the three samples. The 
alginate fibre readily dissolved in PBS (within one hour) due to the ion exchange 
between the fibre and media, resulting in its structure falling apart. However, PCL as 
a protector sheath prevented the fibre from collapsing the alginate structure in 1 hour. 
PCL delayed disintegration of the alginate structure, which affected release of TB from 




shown in Figure 3-29. Not all the TB was released from the Alg fibre, although it 
completely dissolved in PBS as shown in Figure 3-29. This may be due to the uneven 
distribution of TB in the whole fibre with some TB possibly trapped within the PCL 
porous structure. The delay in the release of PCL/CS coaxial fibre in comparison with 
PCL/Alg fibre is significant (inset Figure 3-29); PCL/CS coaxial fibre reaches a 
plateau after 17 hours whereas the CS solid fibre ceased its release after 4 hours 
(Figure 3-29).  
 
Figure 3-29 Cumulative masses of TB released from the 3% w/v chitosan, 3.5% w/v 
alginate solid fibres, and PCL/Alg and PCL/CS coaxial wet-spun fibre and inset is the 
total of 300 hours of release. 
These results demonstrate the capability of coaxial fibres as potential drug carriers. 
Both hydrophobic and hydrophilic drugs can be loaded either into the PCL 
(hydrophobic) or into CS and Alg (hydrophilic) fibres. Release profiles may improve 




3.7.2.6 Effect of cross-linker on morphology of PCL/Alg fibres 
Using a coagulation bath to crosslink the core of coaxial fibres was challenging when 
the diameter of the sheath increased. Therefore, addition of a cross-linker dissolved in 
the core was tried to overcome this issue. 
CaSO4 and CaCO3 are commonly used Ca
2+ sources that rely on internal gelling 
through the release of calcium ions. CaCO3 was added to 3.5% w/v alginate solution, 
yielding a 15 mM final concentration just before extrusion and the solution vortexed 
for 30 s to allow the homogeneous distribution of CaCO3. Glucono-δ-lactone (GDL) 
(30 mM) was then added to the alginate/ CaCO3 solution just before fibre extrusion. 
CaCO3 is not readily soluble in water at neutral pH and since calcium ions are not free 
when was added to the alginate solution, gelation was not initiated. Mixing with GDL 
improved CaCO3 solubility as GDL slowly acidified the alginate/ CaCO3, driving the 
release of calcium ions. Gelation started 30 min after addition of GDL[122,123]. Figure 
3-30 shows the cross-section morphology of wet-sun fibres using CaCl2 as alginate’s 
cross-linker, compared to the PCL/Alg coaxial fibre with CaCO3/GDL cross-linker. 
This method allowed us to alter the sheath diameter, allowing more control over 
formation of the hydrogel structure.  
 
Figure 3-30 LV-SEM images of a cross-section of a) PCL/Alg coaxial fibre in CaCl2 
coagulation bath, b) PCL/Alg coaxial fibre in a water bath and using CaCO3/GDL as 
a cross-linker, and c) higher magnification of alginate fibre in wet-state. 
3.7.2.7 Effect of cross-linker on morphology of PCL/CS fibre 
The crosslinking of CS has been reported with crosslinkers such a glutaraldehyde 
(GA)[124], genipin[125], and epoxides[126]. However, besides genipin, these crosslinking 
agents are synthetically derived. Genipin is naturally derived, biocompatible cross-
linker which has 5000 –10,000 times less cytotoxicity than GA[125]. Genipin reacts 
with compounds containing primary amines, such as chitosan, to form covalently 





Figure 3-31 Genipin chemical structure. 
In our wet-spun chitosan fibres, crosslinking occurred by altering the pH of chitosan. 
1M NaOH was used as coagulation bath (pH~12), promoting the crosslinking of 
chitosan. However, this method has drawbacks such as difficulty in removing NaOH 
from the fibre and difficulty in diffusing the NaOH by increasing the sheath diameter 
in coaxial fibre. Genipin may overcome these drawbacks. In this experiment, genipin 
was dissolved in acetic acid then varying concentrations of genipin (100 mM to 400 
mM) were added to the chitosan solution and the resulting solutions stirred for 30 min. 
The reaction mechanism of chitosan with genipin is based on two reactions that 
proceed at different rates: the first is a nucleophilic attack on genipin by a primary 
amine group that leads to the formation of a heterocyclic compound of genipin linked 
to the glucosamine residue in chitosan, and the second and slower reaction is the 
nucleophilic substitution of the ester group possessed by genipin to form a secondary 
amide link with chitosan. Figure 3-32 shows the cross-section morphology of coaxial 
fibre before and after addition of genipin. A slight change in morphology of the sheath 
(PCL) in PCL/CS coaxial fibre wet-spun in NaOH coagulation bath was observed. 
Since removing the NaOH from the fibre was challenging, it can result in damage to 
the morphology of PCL. Moreover, diffusion of NaOH into the core proved difficult 
when increasing the sheath diameter. However, addition of genipin into the core 







Figure 3-32 LV-SEM images of cross-section of a) PCL/CS coaxial fibre in 1M NaOH 
coagulation bath, b) PCL/CS coaxial fibre in a water bath with genipin as a cross-
linker, c) higher magnification of chitosan fibre in wet-state, and d) higher 
magnification of PCL/CS interface in coaxial fibre. 
 
The gelation time of chitosan was crucial for wet-spinning and was obtained through 
rheology studies. Liquid samples (chitosan solution) were transferred into a rheometer 
plate immediately after mixing (t = 0). The time sweeping procedure was used to test 
samples and the measurement stopped at 500 min. Gelation time was measured by 
cross-point of Storage moduli G′ and loss moduli G′′. Figure 3-33 shows the storage 
modulus (G′) and loss moduli (G′′) as a function of time (t) for genipin at various 
concentrations (100-400 mM). The results showed that 200 mM and 400 mM are ideal 
concentrations of genipin for wet-spinning. Gelation of chitosan began after 
approximately 1 hour of mixing 100 mM genipin, and 20 min for 400 mM genipin, 
therefore, genipin must be added immediately before extrusion (Table 3-9). This 
method may remove limitations of altering the diameter of sheath and washing process 
of fibres. This is important as the washing process may inadvertently wash out drugs 





Figure 3-33 Storage modulus (G′) and loss modulus (G′′) as a function of time (t) for 
genipin in different concentration.  
Table 3-9 Gelation time of chitosan solution after addition of different concentration 
of genipin. 
Sample Gelation time (min) 
100 mM genipin 182.45 
200 mM genipin 66.59 




4 CONCLUSIONS AND FUTURE WORK 
The main aim of this thesis was to develop biodegradable coaxial fibres based on wet-
spinning method for biomedical applications. Coaxial PCL/Alg, and PCL/CS wet-spun 
fibres were fabricated for the first time using coaxial wet-spinning method. The 
spinnability, morphological, mechanical, and thermal properties of fibres were studied. 
The solubility of PCL was investigated in THF, DMF, acetone, DCM, EtOH, MetOH, 
IPA, and chloroform. 
The results showed that PCL is soluble in THF, DCM, DMF, acetone, and chloroform. 
Different concentration of PCL (5-20% w/v) was dissolved in DCM, acetone, DMF, 
and chloroform. PCL (15% w/v) in DMF, DCM, and acetone or 20% w/v PCL in 
chloroform are suitable concentration levels for obtaining continuous, uniform fibres. 
After selecting the suitable solution, the desirable coagulation bath was chosen for 
each fibre. Water was used as a PCL/DMF coagulation bath and MeOH/water 70/30 
v/v was used as the non-solvent for PCL dissolved in DCM and chloroform. 
Water/EtOH 70/30 v/v was used as PCL/acetone coagulation bath. 
Fibres with different diameters were produced. Their diameter can be altered by 
varying the flow rate and needle gauge. Morphological properties of these four PCL 
fibres were studied. PCL/DMF fibre has a porous cross-section structure with pore 
sizes larger than the ones in PCL/acetone fibres. Such porous structures of PCL/DMF 
and PCL/acetone show potential advantages for future drug delivery applications. 
PCL/DCM and chloroform fibres had a dense structure. To utilise fibres in a 
biomedical application, their mechanical properties must be investigated. 
According to our study, PCL/DMF fibre have a lower Young’s modulus of 18.2 ± 
1.2MPa, and then PCL/acetone fibre’s Young’s modulus is 98.9 ± 14.3 MPa, 
PCL/DCM fibres have the highest Young’s modulus of 214.9 ± 55.1MPa. Young’s 
modulus in fibres shows their stiffness. Fibres with lower Young’s modulus are softer. 
Therefore, they are easy to handle and most importantly they may be compatible with 
soft tissues in terms of mechanical properties. Body tissues that are classified as soft 
tissues exhibit significantly lower Young’s modulus.  
PCL/DMF and PCL/acetone fibres have larger elongation of about 400-500% at their 




can be improved and their diameter can be decreased. Due to the PCL/DMF and 
PCL/acetone fibres’ better properties, thermal characteristics of these two fibres were 
compared with PCL pellets. The results showed that the solvent does not affect the 
melting point of the PCL but changes its % crystallinity. 
Spinnability of different concentrations of chitosan was examined. The results showed 
that 3% w/v chitosan had the best spinnability and mechanical properties. Chitosan 
fibres were spun in 1M NaOH in water/ethanol 90/10 v/v coagulation bath. 
This produced fibres with a diameter of 193.6 ± 6.1 µm. SEM images of the fibres 
showed that chitosan has a smooth surface with a porous cross-section structure in 
wet-state. This means that it is a suitable candidate for drug delivery structures. There 
is a slight difference between 2% and 3 %w/v chitosan Young’s modulus (2%: 2.7 ± 
0.4 GPa and 3%: 3.4 ± 0.8 GPa). Chitosan (3% w/v) has a larger elongation break.  
Chitosan fibres in the dry state are brittle and difficult to handle due to their larger 
Young’s modulus. The other hydrogel that has potential to be utilise as a core in 
coaxial fibre is alginate. 0.5-3.5% w/v range of concentration of alginate was prepared 
and spinnability of these solutions was investigated. 2-3.5 %w/v alginate is spinnable 
in 2% CaCl2 in 20% v/v EtOH. Due to the higher loading capacity of 3.5% w/v 
alginate, further characterization was conducted with this concentration. A spinning 
condition such as flow rate, draw ratio, and solvent/non-solvent combination has a 
large impact on the properties of wet-spun fibres. In order to investigate the effect of 
flow rate on wet-spun fibres, 3.5% w/v alginate fibres were wet-spun with three 
different flow rates of 5, 15, and 50 mL.h-1. Higher flow rate results in higher Young’s 
modulus and firm fibres. Flow rate has an impact on ultimate stress but doesn’t affect 
fibre’s elongation at break. 
Hollow PCL, PCL/Alg, and PCL/CS coaxial fibres were successfully fabricated by 
wet-spinning with coaxial spinneret. Coagulation bath was chosen according to the 
core material. 2% CaCl2 and 1M NaOH were used as a coagulant of PCL/Alg and 
PCL/CS coaxial fibres. Unlimited length of fibres was fabricated by this method. SEM 
and optical images of the cross-section of PCL/Alg and PCL/CS showed a cylinder 
shaped hydrogel covered with PCL sheath. The effect of the core flow rate on the 
diameter of the fibre and the sheath was studied. By increasing the core flow rate, the 




dehydrated, and rehydrated states of these fibres were imaged and showed that the 
fibres return to their initial state by placing in PBS or water.  
The mechanical properties of PCL/Alg and PCL/CS coaxial wet-spun fibres were 
discussed. Coaxial fibres still have a low Young’s modulus that shows the possibility 
of compatibility with body’s soft tissues in future biomedical applications. Coaxial 
fibres are capable of being loaded with either hydrophilic or hydrophobic drugs as 
TBO release studies were done. TBO was used as a model to investigate the release 
profile of coaxial fibres against hydrogel solid fibres. Since hydrogels have a burst 
release, PCL fibre as a hydrophobic structure covers the alginate and chitosan structure 
to prevent them from falling apart and burst releasing.  
The release of TBO is delayed by using PCL as a sheath. However, this can be 
improved and more delayed by optimising the structure. The diameter of the sheath 
can be increased by altering the flow rate, however, the only obstacle here is the 
difficulty with diffusing the coagulation bath into the core to cross-link the hydrogel. 
To overcome this obstacle, other types of cross-linkers were utilised to ensure that by 
increasing the diameter of sheath, hydrogels can still be cross-linked. CaCO3/GDL was 
incorporated into the alginate solution and genipin was incorporated into the chitosan 
solution immediately before fibre extrusion. Rheology properties of the incorporation 
of genipin into chitosan were investigated in order to obtain gelation time. Using 
different concentration levels of Genipin, different gelation times were obtained. 
Depending on the wet-spinning process duration, the gelation time can be adjusted.  
FUTURE WORK 
Since our proposed coaxial fibre demonstrated great potential toward drug delivery 
system, further characterization must be performed. Next step to utilise coaxial fibres 
is to integrate them into knitted or braided structures. Employing these assemblies 
provide higher drug release efficiency. Anti-cancer drugs such as Gemcitabine, 
Paclitaxel, and Doxorubicin can be incorporated into the coaxial fibre. FTIR analysis 
must be conducted to investigate the possible interaction between the drug and the 
polymer. Biocompatibility tests must be performed in order to improve the structure 
as an implantable drug carrier. In-vivo and In-vitro release studies of real drugs from 
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